NO20076566L - Ny fremgangsmate for behandling av hyperlipidemi - Google Patents

Ny fremgangsmate for behandling av hyperlipidemi

Info

Publication number
NO20076566L
NO20076566L NO20076566A NO20076566A NO20076566L NO 20076566 L NO20076566 L NO 20076566L NO 20076566 A NO20076566 A NO 20076566A NO 20076566 A NO20076566 A NO 20076566A NO 20076566 L NO20076566 L NO 20076566L
Authority
NO
Norway
Prior art keywords
hyperlipidemia
treatment
new method
hmg
preventing
Prior art date
Application number
NO20076566A
Other languages
English (en)
Inventor
Tomoyuki Nishimoto
Ryuichi Tozawa
Takeo Wada
Eiichiro Ishikawa
Toshiya Nishi
Hiroko Yamakawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20076566L publication Critical patent/NO20076566L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En farmasøytisk sammensetning anvendelig for å hindre og/eller behandle hyperlipidemi som innbefatter å kombinere en effektiv mengde skvalensyntaseinhibitor og HMG-CoA-reduktaseinhibitor er tilveiebrakt.
NO20076566A 2005-06-01 2007-12-19 Ny fremgangsmate for behandling av hyperlipidemi NO20076566L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68587105P 2005-06-01 2005-06-01
US72832905P 2005-10-20 2005-10-20
PCT/JP2006/311362 WO2006129859A2 (en) 2005-06-01 2006-05-31 Combinations of a squalene synthase inhibitor and a hmg-coa reductase inhibitor for treating hyperlipidemia

Publications (1)

Publication Number Publication Date
NO20076566L true NO20076566L (no) 2008-02-22

Family

ID=36699172

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076566A NO20076566L (no) 2005-06-01 2007-12-19 Ny fremgangsmate for behandling av hyperlipidemi

Country Status (17)

Country Link
US (1) US20090209510A1 (no)
EP (1) EP1962832A2 (no)
JP (1) JP2008542191A (no)
KR (1) KR20080012916A (no)
AR (1) AR054368A1 (no)
AU (1) AU2006253255A1 (no)
BR (1) BRPI0610484A2 (no)
CA (1) CA2609784A1 (no)
CR (1) CR9521A (no)
IL (1) IL187207A0 (no)
MA (1) MA29531B1 (no)
MX (1) MX2007014730A (no)
NO (1) NO20076566L (no)
PE (1) PE20070603A1 (no)
RU (1) RU2007149337A (no)
TW (1) TW200714280A (no)
WO (1) WO2006129859A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
MY157189A (en) * 2008-01-10 2016-05-13 Takeda Pharmaceutical Capsule formulation
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
JP5980900B2 (ja) 2011-04-08 2016-08-31 ゾラ バイオサイエンシーズ オサケ ユキチュア スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
US11833133B2 (en) 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
AU5140993A (en) * 1992-10-06 1994-04-26 Merck & Co., Inc. Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith
RU2040932C1 (ru) * 1993-12-17 1995-08-09 Крестьянское хозяйство "Агрофирма Дижа" Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения
JP3479796B2 (ja) * 1995-09-13 2003-12-15 武田薬品工業株式会社 ベンゾオキサゼピン化合物
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
WO1997048701A1 (en) * 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HUP0301301A2 (hu) * 2000-06-23 2003-08-28 Takeda Chemical Industries Ltd. Benzoxazepinon-származékok és szkvalén szintáz inhibitorként való alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
CN1473053A (zh) * 2000-11-09 2004-02-04 ����ҩƷ��ҵ��ʽ���� 高密度脂蛋白-胆甾醇含量提高剂
ATE253353T1 (de) * 2001-04-12 2003-11-15 Vesifact Ag Coenzym q10 enthaltende mikroemulsion- prekonzentrate und mikroemulsionen
EP1407782A4 (en) * 2001-06-28 2004-10-20 Takeda Chemical Industries Ltd AGENTS FOR PREVENTION / TREATMENT OF FUNCTIONAL ORGANIC DISEASES AND ORGANIC DYSFUNCTION
CA2513170A1 (en) * 2003-01-17 2004-08-05 Takeda Pharmaceutical Company Limited Skeletal muscle protecting agent

Also Published As

Publication number Publication date
JP2008542191A (ja) 2008-11-27
US20090209510A1 (en) 2009-08-20
RU2007149337A (ru) 2009-07-10
MA29531B1 (fr) 2008-06-02
AU2006253255A1 (en) 2006-12-07
MX2007014730A (es) 2008-02-15
TW200714280A (en) 2007-04-16
WO2006129859A3 (en) 2007-04-19
CA2609784A1 (en) 2006-12-07
WO2006129859A2 (en) 2006-12-07
IL187207A0 (en) 2008-06-05
AR054368A1 (es) 2007-06-20
EP1962832A2 (en) 2008-09-03
PE20070603A1 (es) 2007-06-22
KR20080012916A (ko) 2008-02-12
CR9521A (es) 2008-02-22
BRPI0610484A2 (pt) 2017-01-31

Similar Documents

Publication Publication Date Title
NO20091544L (no) Sammensetninger av CHK1 inhibitorer
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2007092622A3 (en) Compositions and methods for treating bone
WO2008127275A3 (en) Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
NO20081042L (no) PPAR aktive forbindelser
SG155163A1 (en) Pharmacokinetically improved compounds
EP2666472A3 (en) Uses and compositions for treatment of psoriatic arthritis
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
WO2007109105A3 (en) Flavivirus inhibition by sultams and related compounds
DK1704859T3 (da) Kontrol af androgen receptor-afhængig genenkspression ved inhibering af amin-oxidase-aktiviteten af lysin-specifik demetylase (LSD1)
WO2008045507A3 (en) Substituted tetracycline compounds for treatment of bacillus anthracis infections
CR9521A (es) Metodo novedoso de tratamiento de la hiperlipedemia
WO2006089087A9 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
NO20075321L (no) Fremgangsmate for bronnbehandling og konstruksjon
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
WO2006121719A3 (en) Soluble epoxide hydrolase inhibitors and methods of using same
BRPI0509926A (pt) imidazóis
ATE512967T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
BRPI0507859A (pt) uso dos inibidores da colinesterase
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application